Glenview, ILNCT07450547Now EnrollingIRB Ready

Exocrine Pancreatic Insufficiency (EPI) Clinical Trial in Glenview, IL

Access cutting-edge exocrine pancreatic insufficiency (epi) treatment through this clinical trial at a research site in Glenview. Study-provided care at no cost to qualified participants.

Sponsored by Anagram Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Glenview location

Preparing your pre-screening questions…

Expert Care in Glenview

Access exocrine pancreatic insufficiency (epi) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related exocrine pancreatic insufficiency (epi) treatment provided free

Apply for This Glenview Location

Check if you qualify for this exocrine pancreatic insufficiency (epi) clinical trial in Glenview, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Glenview

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Glenview site if eligible
  4. 4Begin participation

About This Exocrine Pancreatic Insufficiency (EPI) Study in Glenview

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

Sponsor: Anagram Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
Confirmed and documented diagnosis of CF
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
Adequate nutritional status measured by body mass index (BMI) defined by:
BMI ≥25th percentile for children aged 12-17 years
BMI ≥18.5 kg/m2 for ≥18 years of age

Exclusion Criteria

History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD\&C Blue #2).
Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as \<1 bowel movement/week.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Glenview?

Yes, this clinical trial (NCT07450547) has an active research site in Glenview, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Exocrine Pancreatic Insufficiency (EPI) Treatment Options in Glenview, IL

If you're searching for exocrine pancreatic insufficiency (epi) treatment options in Glenview, IL, this clinical trial (NCT07450547) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Glenview research site is actively enrolling participants for this clinical trial. You'll receive care from experienced exocrine pancreatic insufficiency (epi) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all exocrine pancreatic insufficiency (epi) clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Glenview, IL

See all interstitial cystitis clinical trials recruiting in Glenview — not just this study.

Browse Interstitial Cystitis Trials in Glenview →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Glenview?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Glenview, IL